Stocks Health care ALEC
NASDAQ · Health careAlector, Inc. (ALEC)
Alector, Inc. brought in $173.4M of revenue over the twelve months to September 30, 2026, up 151.1% from a year earlier. Net income was $41.4M, a net margin of 23.9%. In fiscal 2025 capital spending exceeded operating cash flow by $184.1M. At September 30, 2026 it held $75.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Alector, Inc.
- Net worth
- Alector, Inc. has a market value (market cap) of $276.4M at the latest share price, and shareholders' equity of $116.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $21M (-79.1% year on year), with a net loss of $142.9M. Over the 12 months to September 30, 2026: revenue $173.4M, net income $41.4M.
- Cash flow
- In fiscal 2025 operations used $184M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Alector, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Alector, Inc. does
Alector, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ALEC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $21M | -$142.9M | -$1.39 | -$184.1M |
| 2024 | $100.6M | -$119M | -$1.23 | -$231.2M |
| 2023 | $97.1M | -$130.4M | -$1.56 | -$186.5M |
| 2022 | $133.6M | -$133.3M | -$1.62 | -$24.4M |
| 2021 | $207.1M | -$36.3M | -$0.45 | $295.3M |
| 2020 | $21.1M | -$190.2M | -$2.45 | -$171.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ALEC ranks in Health care
Latest SEC filings
What Alector, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 4,896% to $162.9M versus the same quarter last year; diluted EPS $1.11 versus -$0.34.
- November 5, 2026
- October 26, 2026Passive stake (5% or more) SCHEDULE 13G
- October 23, 2026Passive stake (5% or more) SCHEDULE 13G
- October 16, 2026
- October 14, 2026
- October 5, 2026Quarterly results8-KAlector entered into an exclusive global licensing agreement with Genentech for its AL050 program and will receive a $100 million upfront payment.
- September 18, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 58% to $3.3M versus the same quarter last year; diluted EPS -$0.21 versus -$0.30.
- August 6, 2026
Insider trades
What the people running Alector, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $296.1K worth of shares in the last 90 days and bought none on the open market. 4% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 14, 2026 | Wong-Sarad GracePrincipal Accounting Officer | Received as pay | 55,555 | - |
| October 14, 2026 | Berkley Neil LindsayCFO & Chief Business Officer | Received as pay | 44,567 | - |
| October 14, 2026 | Rosenthal ArnonChief Executive Officer, Director | Received as pay | 217,500 | - |
| September 4, 2026 | Wong-Sarad GracePrincipal Accounting Officer | Soldpre-planned (10b5-1) | 3,625 | $9.1K |
| September 3, 2026 | Berkley Neil LindsayCFO & Chief Business Officer | Sold | 29,251 | $77.9K |
| September 3, 2026 | Rosenthal ArnonChief Executive Officer, Director | Sold | 72,606 | $193.5K |
| September 3, 2026 | Wong-Sarad GracePrincipal Accounting Officer | Sold | 5,165 | $13.8K |
| September 2, 2026 | Wong-Sarad GracePrincipal Accounting Officer | Soldpre-planned (10b5-1) | 656 | $1.8K |
Who owns ALEC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Chen Yu13G, passive with 4 related filers | 9.2% | November 14, 2025 |
| Deep Track Capital, LP13G, passive with 2 related filers | 8.61% | October 23, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 8.4% | September 18, 2026 |
| Arnon Rosenthal13G, passive | 7.4% | February 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 141 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| TCG Crossover Management, LLC | 10,000,000 | 0 |
| Nantahala Capital Management, LLC | 8,636,218 | +5,820,235 |
| BlackRock, Inc. | 7,847,879 | +106,634 |
| Vanguard Capital Management LLC | 4,009,340 | +330,618 |
| Kynam Capital Management, LP | 3,808,494 | +1,808,494 |
| Merck & Co., Inc. | 3,545,719 | 0 |
| Balyasny Asset Management L.P. | 3,247,426 | +312,173 |
| 683 Capital Management, LLC | 3,200,000 | 0 |
| D. E. Shaw & Co., Inc. | 2,959,983 | -372,852 |
| ADAR1 Capital Management, LLC | 2,883,583 | +1,833,583 |
| Vanguard Portfolio Management LLC | 2,820,493 | +236,951 |
| Geode Capital Management, LLC | 2,454,271 | +168,053 |
| Spruce Street Capital LP | 2,101,068 | 0 |
| Millennium Management LLC | 1,988,835 | +9,609 |
| Ikarian Capital, LLC | 1,982,606 | -100,000 |
| State Street Corp | 1,879,765 | +14,239 |
| Jacobs Levy Equity Management, Inc | 1,765,929 | -388,432 |
| Medici Capital LLC | 1,652,520 | 0 |
| Affinity Asset Advisors, LLC | 1,510,000 | +1,010,000 |
| Eversept Partners, LP | 1,423,873 | +72,767 |
Insiders
11 insiders reported holding 5,379,714 shares in total, about $13.3M at the last price.
| Holder | Shares |
|---|---|
| Rosenthal ArnonChief Executive Officer, Director | 3,514,6001,002,500 held indirectly |
| Kenkare-Mitra SaraPresident and Head of R&D | 501,652 |
| Berkley Neil LindsayCFO & Chief Business Officer | 395,216 |
| Wong-Sarad GracePrincipal Accounting Officer | 161,570 |
| Scheller Richard HDirector | 134,899 |
| Lavigne Louis J JrDirector | 128,109 |
| Yaffe KristineDirector | 124,109 |
| Garofalo Elizabeth A.Director | 118,650 |
| Hammond PaulaDirector | 103,609 |
| Desouza Errol BDirector | 98,650 |
Questions about ALEC
What does Alector, Inc. do?
Alector, Inc. is a company in the Health care sector, listed on NASDAQ as ALEC. Its shares trade on NASDAQ under the ticker ALEC.
What is Alector, Inc.'s net worth?
Alector, Inc. has a market value (market cap) of $276.4M at the latest share price, and shareholders' equity of $116.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Alector, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $41.4M on revenue of $173.4M, a net margin of 23.9%.
How much revenue does Alector, Inc. make?
Over the twelve months to September 30, 2026 Alector, Inc. reported revenue of $173.4M. That is 151.1% more than a year earlier.
When did Alector, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Alector, Inc.'s next earnings report?
Alector, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ALEC with
Follow ALEC
Get an email when Alector, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Alector, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.